The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.
Seagen Inc. could be the first to bring a drug to market for HER2-positive metastatic colorectal cancer (mCRC) if the US Food and Drug Administration approves Tukysa (tucatinib) for the expanded indication based on positive Phase II data.
The company is poised to seek accelerated approval from the FDA for the drug in second-line HER2-positive mCRC based on...
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
